These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22633434)

  • 21. Rationale and design: impact of intravascular ultrasound guidance on long-term clinical outcomes of everolimus-eluting stents in long coronary lesions.
    Cho S; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Contemp Clin Trials; 2015 Jan; 40():90-4. PubMed ID: 25433202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo virtual histology intravascular ultrasound comparison of neointimal hyperplasia within drug-eluting- versus bare metal stents.
    Wakabayashi K; Mintz G; Delhaye C; Choi YJ; Doh JH; Ben-Dor I; Gaglia M; Pakala R; Suddath W; Satler L; Kent K; Pichard A; Weissman N; Waksman R
    J Invasive Cardiol; 2011 Jul; 23(7):262-8. PubMed ID: 21725119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term comparative analysis from an all-comer cohort of coronary patients treated using first- and second-generation drug-eluting stents.
    Codner P; Bental T; Assali A; Vaknin-Assa H; Lev E; Kornowski R
    J Invasive Cardiol; 2014 Aug; 26(8):378-84. PubMed ID: 25091097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study.
    Radu MD; Räber L; Kalesan B; Muramatsu T; Kelbæk H; Heo J; Jørgensen E; Helqvist S; Farooq V; Brugaletta S; Garcia-Garcia HM; Jüni P; Saunamäki K; Windecker S; Serruys PW
    Eur Heart J; 2014 Mar; 35(12):795-807. PubMed ID: 24132187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial.
    Jensen LO; Maeng M; Thayssen P; Villadsen A; Krusell L; Botker HE; Pedersen KE; Aaroe J; Christiansen EH; Vesterlund T; Hansen KN; Ravkilde J; Tilsted HH; Lassen JF; Thuesen L
    EuroIntervention; 2011 Jul; 7(3):323-31. PubMed ID: 21729834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
    JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation.
    Im E; Kim BK; Ko YG; Shin DH; Kim JS; Choi D; Jang Y; Hong MK
    Circ Cardiovasc Interv; 2014 Feb; 7(1):88-96. PubMed ID: 24425586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of late stent malapposition after primary stenting in ST-elevation myocardial infarction: a subanalysis of the selection trial.
    Chechi T; Vecchio S; Lilli A; Giuliani G; Spaziani G; Baldereschi G; Montereggi A; Rubboli A; Margheri M
    J Interv Cardiol; 2009 Jun; 22(3):201-6. PubMed ID: 19366402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
    Waseda K; Ako J; Yamasaki M; Koizumi T; Sakurai R; Hongo Y; Koo BK; Ormiston J; Worthley SG; Whitbourn RJ; Walters DL; Meredith IT; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2011 Jun; 4(3):248-55. PubMed ID: 21586691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term vascular changes after drug-eluting stent implantation assessed by serial volumetric intravascular ultrasound analysis.
    Kang SJ; Park DW; Mintz GS; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2010 May; 105(10):1402-8. PubMed ID: 20451685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative dose and vascular response after drug-eluting stent implantation: A dosimetric 3D-intravascular ultrasound study.
    Kitahara H; Waseda K; Yamada R; Sakamoto K; Yock PG; Fitzgerald PJ; Honda Y
    Int J Cardiol; 2016 Feb; 204():211-7. PubMed ID: 26681540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of different stent alloys on human vascular response to everolimus-eluting stent: an optical coherence tomography study: the OCTEVEREST.
    Guagliumi G; Capodanno D; Ikejima H; Bezerra HG; Sirbu V; Musumeci G; Fiocca L; Lortkipanidze N; Vassileva A; Tahara S; Valsecchi O; Costa MA
    Catheter Cardiovasc Interv; 2013 Feb; 81(3):510-8. PubMed ID: 22431208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of vascular remodeling in patients treated with sirolimus-versus zotarolimus-eluting stent following acute myocardial infarction.
    Kang KW; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Jang Y; Hong MK
    Clin Cardiol; 2012 Jan; 35(1):49-54. PubMed ID: 22161864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
    Kaul U; Bangalore S; Seth A; Arambam P; Abhaichand RK; Patel TM; Banker D; Abhyankar A; Mullasari AS; Shah S; Jain R; Kumar PR; Bahuleyan CG;
    N Engl J Med; 2015 Oct; 373(18):1709-19. PubMed ID: 26466202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.